Oligometastatic PCa diagnosed using \[68Ga\]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous metastases and/or M1c ≤3 lung metastases
Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, Platelets ≥100 x 109 /L and Haemoglobin ≥9 g/dL.
Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
Patients must be able to sign Informed Consent Form
You may not be if
Concomitant participation in any other interventional trial
Concurrent severe oncologic and medical conditions that result in patients not having a life expectancy of longer than the duration of the trial.
Nonmetastatic PCa on \[68Ga\]Ga-PSMA-11 imaging
\>5 osseous metastases on \[68Ga\]Ga-PSMA-11 imaging
Visceral metastases, apart from lungs
Age \> 75 years.
Ongoing or previous androgen deprivation therapy with agonist or antagonist therapies.
Presence of clinically relevant somatic or psychiatric diseases that might interfere with the objectives and assessments of the study.
Complete urinary out-flow obstruction or severe unmanageable urinary incontinence
Clareo Health | Neoadjuvant PSMA-RLT in Oligometastatic PCa
